Tandem Diabetes Care, Inc.
Viés de alta
Atualizado

Tandem is oversold going into ER month

264
The recent analyst day was great, in my opinion, with strong product pipeline which should be followed by strong delivery. Guidance is up and most likely conservative going into next month's earnings call. Short term headwinds with regards to overbought status should dissipate soon as Tandem is far from being overbought. It has a strong chance of becoming a market leader a few years down the road, especially with international expansion. Control-IQ and t:sport will propel the stock to new highs.
Trade fechado: stop atingido

Aviso legal

As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.